Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

August 19, 2022

Study Completion Date

September 12, 2022

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

NDI-034858 study drug

NDI-034858 2 mg oral capsules.

DRUG

NDI-034858 study drug

NDI-034858 5 mg oral capsules.

DRUG

NDI-034858 study drug

NDI-034858 15 mg oral capsules.

DRUG

NDI-034858 study drug

NDI-034858 30 mg (2\*15 mg) oral capsules.

OTHER

Placebo

Placebo matched to NDI-034858 oral capsules.

Trial Locations (69)

10075

Nimbus site 143, New York

15123

Nimbus site 125, Pittsburgh

20850

Nimbus site 122, Rockville

28277

Nimbus site 129, Charlotte

28405

Nimbus site 106, Wilmington

29407

Nimbus site 110, Charleston

30328

Nimbus site 119, Sandy Springs

31217

Nimbus site 150, Macon

31904

Nimbus site 147, Columbus

33012

Nimbus site 149, Hialeah

33014

Nimbus site 107, Miami Lakes

Nimbus site 139, Miami Lakes

33063

Nimbus site 160, Margate

33122

Nimbus site 155, Doral

33172

Nimbus site 157, Sweetwater

33406

Nimbus site 116, West Palm Beach

33607

Nimbus site 101, Tampa

33613

Nimbus site 102, Tampa

33770

Nimbus site 130, Largo

34470

Nimbus site 118, Ocala

35205

Nimbus site 137, Birmingham

35244

Nimbus site 156, Birmingham

37215

Nimbus site 121, Nashville

38305

Nimbus site 117, Jackson

40217

Nimbus site 161, Louisville

40241

Nimbus site 105, Louisville

43209

Nimbus site 127, Bexley

43213

Nimbus site 145, Columbus

45324

Nimbus site 128, Fairborn

46250

Nimbus site 140, Indianapolis

47129

Nimbus site 159, Clarksville

48084

Nimbus site 112, Troy

Nimbus site 138, Troy

48103

Nimbus site 146, Ann Arbor

48706

Nimbus site 103, Bay City

55112

Nimbus site 158, New Brighton

60077

Nimbus site 123, Skokie

66210

Nimbus site 154, Overland Park

70006

Numbus site 114, Metairie

70605

Nimbus site 136, Lake Charles

72022

Nimbus site 133, Bryant

73071

Nimbus site 141, Norman

76011

Nimbus site 109, Arlington

77401

Nimbus site 113, Bellaire

77494

Nimbus site 131, Katy

77598

Nimbus site 162, Webster

78213

Nimbus site 104, San Antonio

78229

Nimbus site 152, San Antonio

85255

Nimbus site 132, Scottsdale

90033

Nimbus site 108, Los Angeles

91403

Nimbus site 120, Sherman Oaks

92122

Nimbus site 153, San Diego

92123

Nimbus site 111, San Diego

92708

Nimbus site 134, Fountain Valley

95405

Nimbus site 148, Santa Rosa

95816

Nimbus site 124, Sacramento

99026

Nimbus site 142, Spokane

01915

Nimbus site 115, Beverly

02169

Nimbus site 135, Quincy

Unknown

Nimbus site 204, Calgary

Nimbus site 206, Calgary

Nimbus site 212, Edmonton

Nimbus site 209, Hamilton

Nimbus site 203, Markham

Nimbus site 201, Montreal

Nimbus site 205, Oshawa

Nimbus site 210, Peterborough

Nimbus site 208, Red Deer

Nimbus site 202, Waterloo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Innovaderm Research Inc.

OTHER

collaborator

Nimbus Lakshmi, Inc.

INDUSTRY

lead

Takeda

INDUSTRY

NCT04999839 - Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter